Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) ca...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rumi, Elisa, Pietra, Daniela, Pascutto, Cristiana, Guglielmelli, Paola, Martínez-Trillos, Alejandra, Casetti, Ilaria, Colomer, Dolors, Pieri, Lisa, Pratcorona, Marta, Rotunno, Giada, Sant’Antonio, Emanuela, Bellini, Marta, Cavalloni, Chiara, Mannarelli, Carmela, Milanesi, Chiara, Boveri, Emanuela, Ferretti, Virginia, Astori, Cesare, Rosti, Vittorio, Cervantes, Francisco, Barosi, Giovanni, Vannucchi, Alessandro M., Cazzola, Mario
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133481/
https://ncbi.nlm.nih.gov/pubmed/24986690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-05-578435
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares